ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics

巻 17, 発行 2, 2012, pp. 175-198
DOI: 10.1615/CritRevOncog.v17.i2.40
Get accessGet access

要約

The cell cycle is a tightly regulated series of events that governs cell replication and division. Deregulation of cell cycle kinases, e.g., cyclin-dependent kinases (CDKs), can initiate a hyper-proliferative cell phenotype and cause genomic instability, thus facilitating malignant transformation. Pharmacological agents targeting CDKs have been developed as potential anti-cancer agents for over 20 years, evolving from early pan-CDK inhibitors to second-generation inhibitors with much greater specificity and selectivity. Despite these advances in drug design and highly successful preclinical investigations, CDK inhibitors have yet to achieve their expected efficacy in clinical trials. In addition, inhibitors of other cell cycle kinases are currently progressing through clinical trials. Recent biochemical and genetic studies might be used to improve the effectiveness of cell cycle kinase inhibitors as anti-cancer agents through better drug design, therapeutic combinations, and patient selection.

によって引用された
  1. Bayraktar Soley, Rocha Lima Caio M, Emerging cell-cycle inhibitors for pancreatic cancer therapy, Expert Opinion on Emerging Drugs, 17, 4, 2012. Crossref

  2. Hannan K.M., Sanij E., Rothblum L.I., Hannan R.D., Pearson R.B., Dysregulation of RNA polymerase I transcription during disease, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1829, 3-4, 2013. Crossref

  3. Rubin Seth M., Deciphering the retinoblastoma protein phosphorylation code, Trends in Biochemical Sciences, 38, 1, 2013. Crossref

  4. Yuan Xiao-Sun, Zhang Yi, Guan Xiao-Ya, Dong Bin, Zhao Min, Mao Lin-Lin, Lu You-Yong, Tian Xiu-Yun, Hao Chun-Yi, p42.3: A promising biomarker for the progression and prognosis of human colorectal cancer, Journal of Cancer Research and Clinical Oncology, 139, 7, 2013. Crossref

  5. Galons Hervé, Oumata Nassima, Gloulou Olfa, Meijer Laurent, Cyclin-dependent kinase inhibitors closer to market launch?, Expert Opinion on Therapeutic Patents, 23, 8, 2013. Crossref

  6. Finn Richard S, Crown John P, Lang Istvan, Boer Katalin, Bondarenko Igor M, Kulyk Sergey O, Ettl Johannes, Patel Ravindranath, Pinter Tamas, Schmidt Marcus, Shparyk Yaroslav, Thummala Anu R, Voytko Nataliya L, Fowst Camilla, Huang Xin, Kim Sindy T, Randolph Sophia, Slamon Dennis J, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, The Lancet Oncology, 16, 1, 2015. Crossref

  7. Dienstmann Rodrigo, Dong Fei, Borger Darrell, Dias-Santagata Dora, Ellisen Leif W., Le Long P., Iafrate A. John, Standardized decision support in next generation sequencing reports of somatic cancer variants, Molecular Oncology, 8, 5, 2014. Crossref

  8. Zhou Dong-Hu, Wang Xuemin, Yang Mingmin, Shi Xiaoyan, Huang Wenbin, Feng Qing, Combination of Low Concentration of (−)-Epigallocatechin Gallate (EGCG) and Curcumin Strongly Suppresses the Growth of Non-Small Cell Lung Cancer in Vitro and in Vivo through Causing Cell Cycle Arrest, International Journal of Molecular Sciences, 14, 6, 2013. Crossref

  9. Antonucci Lisa A, Egger Jacklynn V, Krucher Nancy A, Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax, Cell Cycle, 13, 22, 2014. Crossref

  10. McCloy Rachael A, Rogers Samuel, Caldon C Elizabeth, Lorca Thierry, Castro Anna, Burgess Andrew, Partial inhibition of Cdk1 in G2phase overrides the SAC and decouples mitotic events, Cell Cycle, 13, 9, 2014. Crossref

  11. Fletcher Steven, Prochownik Edward V., Small-molecule inhibitors of the Myc oncoprotein, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1849, 5, 2015. Crossref

  12. Lim Felicia Phei Lin, Dolzhenko Anton V., 1,3,5-Triazine-based analogues of purine: From isosteres to privileged scaffolds in medicinal chemistry, European Journal of Medicinal Chemistry, 85, 2014. Crossref

  13. Lubanska Dorota, Market-Velker Brenna A., deCarvalho Ana C., Mikkelsen Tom, Fidalgo da Silva Elizabeth, Porter Lisa A., The Cyclin-like Protein Spy1 Regulates Growth and Division Characteristics of the CD133+ Population in Human Glioma, Cancer Cell, 25, 1, 2014. Crossref

  14. Shcherba Marina, Liang Yuanxin, Fernandes David, Perez-Soler Roman, Cheng Haiying, Cell cycle inhibitors for the treatment of NSCLC, Expert Opinion on Pharmacotherapy, 15, 7, 2014. Crossref

  15. Toogood Peter L., Ide Nathan D., Palbociclib (Ibrance): The First-in-Class CDK4/6 Inhibitor for Breast Cancer, in Innovative Drug Synthesis, 2015. Crossref

  16. Egger Jacklynn V., Lane Maria V., Antonucci Lisa A., Dedi Brixhilda, Krucher Nancy A., Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb, Cancer Biology & Therapy, 17, 11, 2016. Crossref

  17. Ahn Daniel H., Javle Milind, Ahn Chul W., Jain Apurva, Mikhail Sameh, Noonan Anne M., Wu Christina, Shroff Rachna T., Chen James L., Bekaii-Saab Tanios, Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance, Cancer, 122, 23, 2016. Crossref

  18. Gubern Albert, Joaquin Manel, Marquès Miriam, Maseres Pedro, Garcia-Garcia Javier, Amat Ramon, González-Nuñez Daniel, Oliva Baldo, Real Francisco X., de Nadal Eulàlia, Posas Francesc, The N-Terminal Phosphorylation of RB by p38 Bypasses Its Inactivation by CDKs and Prevents Proliferation in Cancer Cells, Molecular Cell, 64, 1, 2016. Crossref

  19. Mariaule Gaëlle, Belmont Philippe, Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey, Molecules, 19, 9, 2014. Crossref

  20. Ferrari Stefano, Gentili Christian, Maintaining Genome Stability in Defiance of Mitotic DNA Damage, Frontiers in Genetics, 7, 2016. Crossref

  21. Lu Fang, Xue Jian-xin, Hu Yu-chang, Gan Lu, Shi Yi, Yang Han-shuo, Wei Yu-quan, Rameshwar Pranela, CARP Is a Potential Tumor Suppressor in Gastric Carcinoma and a Single-Nucleotide Polymorphism in CARP Gene Might Increase the Risk of Gastric Carcinoma, PLoS ONE, 9, 5, 2014. Crossref

  22. Hazel Pascale, Kroll Sebastian H. B., Bondke Alexander, Barbazanges Marion, Patel Hetal, Fuchter Matthew J., Coombes R Charles, Ali Simak, Barrett Anthony G. M., Freemont Paul S., Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study, ChemMedChem, 12, 5, 2017. Crossref

  23. Benicio Lucas Milanez, Simionato Ane Stefano, Novello Cláudio Roberto, Guimarães Jeconias Rocha, Felicidade Ingrid, de Oliveira Admilton Gonçalves, de Mello João Carlos Palazzo, Mantovani Mário Sérgio, Chryssafidis Andreas Lazaros, Andrade Galdino, de Syllos Colus Ilce Mara, de Oliveira Marcelo Tempesta, RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa, Scientific Reports, 8, 1, 2018. Crossref

  24. Jeong Eun-Hui, Lee Tae-Gul, Ko Yun Jung, Kim Seo Yun, Kim Hye-Ryoun, Kim Hyunggee, Kim Cheol Hyeon, Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells, Cellular Oncology, 41, 6, 2018. Crossref

  25. McGrath Denise A, Fifield Bre‐Anne, Marceau Aimee H, Tripathi Sarvind, Porter Lisa A, Rubin Seth M, Structural basis of divergent cyclin‐dependent kinase activation by Spy1/ RINGO proteins , The EMBO Journal, 36, 15, 2017. Crossref

  26. Protzel C., Hakenberg O. W., New Horizons in the Diagnosis, Treatment, and Prevention of Penile Cancer, in Penile Cancer, 2013. Crossref

  27. Ordulu Zehra, Chai Hongyan, Peng Gang, McDonald Anna G., De Nictolis Michele, Garcia-Fernandez Eugenia, Hardisson David, Prat Jaime, Li Peining, Hui Pei, Oliva Esther, Buza Natalia, Molecular and clinicopathologic characterization of intravenous leiomyomatosis, Modern Pathology, 33, 9, 2020. Crossref

  28. Rojas-Jiménez Ernesto, Mejía-Gómez Javier César, Díaz-Velásquez Clara, Quezada-Urban Rosalía, Martínez Gregorio Héctor, Vallejo-Lecuona Fernando, de la Cruz-Montoya Aldo, Porras Reyes Fany Iris, Pérez-Sánchez Víctor Manuel, Maldonado-Martínez Héctor Aquiles, Robles-Estrada Maybelline, Bargalló-Rocha Enrique, Cabrera-Galeana Paula, Ramos-Ramírez Maritza, Chirino Yolanda Irasema, Alonso Herrera Luis, Terrazas Luis Ignacio, Oliver Javier, Frecha Cecilia, Perdomo Sandra, Vaca-Paniagua Felipe, Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic, Genes, 11, 11, 2020. Crossref

  29. Yuan Kai, Min Wenjian, Wang Xiao, Li Jiaxing, Kuang Wenbin, Zhang Fang, Xie Shengnan, Yang Peng, Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening, Future Medicinal Chemistry, 12, 12, 2020. Crossref

  30. Duan Shengquan, Place David, Perfect Hahdi H., Ide Nathan D., Maloney Mark, Sutherland Karen, Price Wiglesworth Kristin E., Wang Ke, Olivier Mark, Kong Fangming, Leeman Kyle, Blunt Jon, Draper John, McAuliffe Marie, O’Sullivan Maria, Lynch Denis, Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling, Organic Process Research & Development, 20, 7, 2016. Crossref

  31. Maloney Mark T., Jones Brian P., Olivier Mark A., Magano Javier, Wang Ke, Ide Nathan D., Palm Andrew S., Bill David R., Leeman Kyle R., Sutherland Karen, Draper John, Daly Adrian M., Keane Joseph, Lynch Denis, O’Brien Marie, Tuohy Joanne, Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability, Organic Process Research & Development, 20, 7, 2016. Crossref

  32. Mohammed Amrallah A., Rashied Hanaa, Elsayed Fifi Mostafa, CDK4/6 inhibitors in advanced breast cancer, what is beyond?, Oncology Reviews, 13, 2, 2019. Crossref

  33. Kang Jian, Sergio C Marcelo, Sutherland Robert L, Musgrove Elizabeth A, Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells, BMC Cancer, 14, 1, 2014. Crossref

  34. Chekal Brian P., Ewers Jason, Guinness Steven M., Ide Nathan D., Leeman Kyle R., Post Ronald J., Rane Anil M., Sutherland Karen, Wang Ke, Webster Mark, Withbroe Gregory J., Draper John, Lynch Denis, McAuliffe Marie, Keane Joseph, Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control, Organic Process Research & Development, 20, 7, 2016. Crossref

  35. Duan Shengquan, Feng Xichun, Gonzalez Miguel, Bader Scott, Hayward Cheryl, Ljubicic Tomislav, Lu Jiangping, Mustakis Jason, Maloney Mark, Rainville Joseph, Zhang Xin, Developing a Multistep Continuous Manufacturing Process for (1R,2R)-2-Amino-1-methylcyclopentan-1-ol, Organic Process Research & Development, 24, 11, 2020. Crossref

  36. Pye Cameron R., Bray Walter M., Brown Elise R., Burke Jason R., Lokey R. Scott, Rubin Seth M., A Strategy for Direct Chemical Activation of the Retinoblastoma Protein, ACS Chemical Biology, 11, 5, 2016. Crossref

  37. Etemadmoghadam Dariush, Au-Yeung George, Wall Meaghan, Mitchell Chris, Kansara Maya, Loehrer Elizabeth, Batzios Crisoula, George Joshy, Ftouni Sarah, Weir Barbara A., Carter Scott, Gresshoff Irma, Mileshkin Linda, Rischin Danny, Hahn William C., Waring Paul M., Getz Gad, Cullinane Carleen, Campbell Lynda J., Bowtell David D., Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer, Clinical Cancer Research, 19, 21, 2013. Crossref

  38. Stone Andrew, Cowley Mark J., Valdes-Mora Fatima, McCloy Rachael A., Sergio C. Marcelo, Gallego-Ortega David, Caldon C. Elizabeth, Ormandy Christopher J., Biankin Andrew V., Gee Julia M.W., Nicholson Robert I., Print Cristin G., Clark Susan J., Musgrove Elizabeth A., BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer, Molecular Cancer Therapeutics, 12, 9, 2013. Crossref

  39. Oikkonen Jaana, Zhang Kaiyang, Salminen Liina, Schulman Ingrid, Lavikka Kari, Andersson Noora, Ojanperä Erika, Hietanen Sakari, Grénman Seija, Lehtonen Rainer, Huhtinen Kaisa, Carpén Olli, Hynninen Johanna, Färkkilä Anniina, Hautaniemi Sampsa, Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer, JCO Precision Oncology, 3, 2019. Crossref

  40. Garraway Levi A., Genomics-Driven Oncology: Framework for an Emerging Paradigm, Journal of Clinical Oncology, 31, 15, 2013. Crossref

  41. Dana Dibyendu, Das Tuhin, Choi Athena, Bhuiyan Ashif I., Das Tirtha K., Talele Tanaji T., Pathak Sanjai K., Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development, Molecules, 27, 2, 2022. Crossref

  42. Etman Ahmed Mohamed, Abdel Mageed Sherif Sabry, Ali Mohamed Ahmed, El Hassab Mahmoud Abd El Monem, Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story, Current Chemical Biology, 15, 2, 2021. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain